sunnyfang1419 Download PDF
  • 250
  • 2
First Immunotherapy For Early-stage Triple-negative Breast Cancer
On July 27, Merck (MSD) announced that the FDA approved its blockbuster PD-1 antibody therapy Keytruda in combination with chemotherapy, as a neoadjuvant therapy before surgery, then continued as single agent as an adjuvant therapy after surgery, to treat high-risk early-stage triple-negative breast cancer (TNBC) patients.
View Text Version Category : 26
  • Follow
  • 0
  • Embed
  • Share
  • Upload
Related publications